The imposition of tariffs by the United States government has introduced significant uncertainties across various industries, including biotechnology. This white paper examines the potential ramifications of these tariffs on biotech manufacturing, funding, and the localization of clinical trials. Additionally, it evaluates whether there is a discernible trend toward conducting more clinical trials in Europe.
White Paper
The Potential Impact of U.S. Tariffs on the Biotech Sector: Manufacturing, Funding, and Clinical Trials
Download PDF
Related Resources
All Resources

white-paper
The 5 CDMO Execution Gaps (and How to Close Them)
Read More

white-paper
Enterprise AI Starts With People
Read More

case-study
Syner-G Brings a New Radiopharmaceutical Facility Toward GMP Operational Readiness
Read More

case-study
Transforming Product & Portfolio Management Through Responsible, Human-Centric AI
Read More
Let's move from science to success.
Let’s Talk
